Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
| ▸ | SCD5 | Q86SK9 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1166184 | 0.90 | SMN1; SMN2 (0.48) | ALDH1A1MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL1166446 | 0.89 | MEN1 (0.50) | ALDH1A1MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL1166153 | 0.88 | HCRTR1 (0.61) | ALDH1A1MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL1165989 | 0.87 | HCRTR1 (0.51) | ALDH1A1MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL1166519 | 0.87 | HCRTR1 (0.51) | ALDH1A1MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL1166583 | 0.86 | HCRTR1 (0.51) | ALDH1A1MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL1166183 | 0.85 | HCRTR1 (0.49) | ALDH1A1MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL1166708 | 0.84 | HCRTR1 (0.51) | ALDH1A1MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL1167856 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL1166577 | 0.83 | HCRTR1 (0.46) | ALDH1A1MEN1KMT2AMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | claimed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | claimed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | claimed |
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | ALDH1A1 96/4885MEN1 2602/4885KMT2A 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.